Samumed continues to invest in preclinical research, expanding its technology platform while deepening its primary focus on the Wnt pathway. Thus, the company now claims a diverse pipeline of programs in different stages of clinical readiness.

Lead Compound Disease Area
SM04690 Osteoarthritis Phase 3
SM04690 Degenerative Disc Disease Phase 1
SM04646 Idiopathic Pulmonary Fibrosis Phase 1
SM04755 Psoriasis Phase 1
SM04755 Tendinopathy Phase 1
SM04554 Androgenetic Alopecia Phase 3
SM08502 Oncology Phase 1
SM07883 Alzheimer’s Disease Phase 1